Home/Filings/4/0000899243-22-031353
4//SEC Filing

PORFIDO FRANK L. 4

Accession 0000899243-22-031353

CIK 0001537917other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 6:00 PM ET

Size

10.1 KB

Accession

0000899243-22-031353

Insider Transaction Report

Form 4
Period: 2022-09-16
PORFIDO FRANK L.
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Common Stock

    2022-09-1610,0000 total
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16396,8000 total
    Exercise: $0.32Exp: 2032-04-22Common Stock (396,800 underlying)
  • Disposition to Issuer

    Employee Stock Option - Option to buy

    2022-09-16725,0000 total
    Exercise: $1.43Exp: 2031-06-14Common Stock (725,000 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 438 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
  • [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 31,769 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
  • [F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 17,387 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.

Issuer

TYME TECHNOLOGIES, INC.

CIK 0001537917

Entity typeother

Related Parties

1
  • filerCIK 0001866899

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
10.1 KB